Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients

C. Comuzzi, D. Lorenzin, A. Rossetto, M. G. Faraci, D. Nicolini, P. Garelli, V. Bresadola, P. Toniutto, G. Soardo, G. S. Baroni, G. L. Adani, A. Risaliti, U. Baccarani

Research output: Contribution to journalArticle

Abstract

Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.

Original languageEnglish
Pages (from-to)1320-1321
Number of pages2
JournalTransplantation Proceedings
Volume42
Issue number4
DOIs
Publication statusPublished - May 2010

Fingerprint

Tacrolimus
Safety
Liver
Transplant Recipients
Liver Function Tests
Organ Transplantation
Immunosuppressive Agents
Transplants
Kidney

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients. / Comuzzi, C.; Lorenzin, D.; Rossetto, A.; Faraci, M. G.; Nicolini, D.; Garelli, P.; Bresadola, V.; Toniutto, P.; Soardo, G.; Baroni, G. S.; Adani, G. L.; Risaliti, A.; Baccarani, U.

In: Transplantation Proceedings, Vol. 42, No. 4, 05.2010, p. 1320-1321.

Research output: Contribution to journalArticle

Comuzzi, C, Lorenzin, D, Rossetto, A, Faraci, MG, Nicolini, D, Garelli, P, Bresadola, V, Toniutto, P, Soardo, G, Baroni, GS, Adani, GL, Risaliti, A & Baccarani, U 2010, 'Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients', Transplantation Proceedings, vol. 42, no. 4, pp. 1320-1321. https://doi.org/10.1016/j.transproceed.2010.03.106
Comuzzi, C. ; Lorenzin, D. ; Rossetto, A. ; Faraci, M. G. ; Nicolini, D. ; Garelli, P. ; Bresadola, V. ; Toniutto, P. ; Soardo, G. ; Baroni, G. S. ; Adani, G. L. ; Risaliti, A. ; Baccarani, U. / Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients. In: Transplantation Proceedings. 2010 ; Vol. 42, No. 4. pp. 1320-1321.
@article{204aa4f02e1b418bbdacddb9fbff7942,
title = "Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients",
abstract = "Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15{\%} to 55{\%}. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.",
author = "C. Comuzzi and D. Lorenzin and A. Rossetto and Faraci, {M. G.} and D. Nicolini and P. Garelli and V. Bresadola and P. Toniutto and G. Soardo and Baroni, {G. S.} and Adani, {G. L.} and A. Risaliti and U. Baccarani",
year = "2010",
month = "5",
doi = "10.1016/j.transproceed.2010.03.106",
language = "English",
volume = "42",
pages = "1320--1321",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients

AU - Comuzzi, C.

AU - Lorenzin, D.

AU - Rossetto, A.

AU - Faraci, M. G.

AU - Nicolini, D.

AU - Garelli, P.

AU - Bresadola, V.

AU - Toniutto, P.

AU - Soardo, G.

AU - Baroni, G. S.

AU - Adani, G. L.

AU - Risaliti, A.

AU - Baccarani, U.

PY - 2010/5

Y1 - 2010/5

N2 - Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.

AB - Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=77952560702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952560702&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.03.106

DO - 10.1016/j.transproceed.2010.03.106

M3 - Article

C2 - 20534291

AN - SCOPUS:77952560702

VL - 42

SP - 1320

EP - 1321

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -